Scientists turn superbug MRSA into treatable infection
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
List view / Grid view
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
Google has introduced an AI-powered 'co-scientist' designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets.
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
York University researchers have discovered a genetic mutation in the TRAF1 protein that dramatically reduces inflammation, offering a potential breakthrough in rheumatoid arthritis treatment.
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
Researchers at the University of Toronto have discovered a compound in ginger, furanodienone (FDN), that interacts with the pregnane X receptor to reduce inflammation in the colon. This finding suggests FDN could be an effective, natural treatment for inflammatory bowel disease (IBD).
Researchers have identified a small gene, SCN10a-short, that could enable gene therapy to treat malignant cardiac arrhythmias. This discovery offers the potential for a one-time treatment, reducing the reliance on lifelong medication and invasive procedures.
A study by the University of Surrey suggests that amlodipine, a common blood pressure medication, could be repurposed as a safer, more accessible treatment for ADHD. This offers a promising alternative to current medications and highlights the potential of drug repurposing in advancing treatment options.
Researchers at Mount Sinai have created a computational tool that predicts effective drug combinations, providing a faster and more cost-efficient method for identifying potential treatments for complex diseases like cancer.
The FORESIGHT consortium has secured €9 million to speed up drug development using advanced molecular imaging, targeting major diseases like cancer, autoimmune conditions, and heart disorders.
A new UCLA study reveals that DNA mismatch repair genes play a crucial role in Huntington’s disease by driving neuronal damage and motor impairments. Targeting these genes, especially Msh3 and Pms1, could offer promising therapeutic avenues for the disease.